Cutera, Inc., a medical device company, engages in the research, development, manufacture, marketing, and servicing of laser and energy-based aesthetics systems for practitioners worldwide. More Details
Adequate balance sheet and slightly overvalued.
Share Price & News
How has Cutera's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CUTR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: CUTR's weekly volatility (8%) has been stable over the past year.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: CUTR underperformed the US Medical Equipment industry which returned 19.1% over the past year.
Return vs Market: CUTR underperformed the US Market which returned 21% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Cutera's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StCutera's (NASDAQ:CUTR) Shareholders Are Down 54% On Their Shares
6 months ago | Simply Wall StEarnings Update: Cutera, Inc. (NASDAQ:CUTR) Just Reported And Analysts Are Trimming Their Forecasts
6 months ago | Simply Wall StThese Analysts Just Made A Huge Downgrade To Their Cutera, Inc. (NASDAQ:CUTR) EPS Forecasts
Is Cutera undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CUTR ($23.76) is trading below our estimate of fair value ($82.65)
Significantly Below Fair Value: CUTR is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CUTR is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: CUTR is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CUTR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CUTR is overvalued based on its PB Ratio (8.1x) compared to the US Medical Equipment industry average (4.5x).
How is Cutera forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CUTR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CUTR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CUTR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CUTR's revenue (19.8% per year) is forecast to grow faster than the US market (10.3% per year).
High Growth Revenue: CUTR's revenue (19.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CUTR's Return on Equity is forecast to be low in 3 years time (6.2%).
How has Cutera performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CUTR is currently unprofitable.
Growing Profit Margin: CUTR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CUTR is unprofitable, and losses have increased over the past 5 years at a rate of 37.5% per year.
Accelerating Growth: Unable to compare CUTR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CUTR is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (0.2%).
Return on Equity
High ROE: CUTR has a negative Return on Equity (-54.13%), as it is currently unprofitable.
How is Cutera's financial position?
Financial Position Analysis
Short Term Liabilities: CUTR's short term assets ($96.3M) exceed its short term liabilities ($45.1M).
Long Term Liabilities: CUTR's short term assets ($96.3M) exceed its long term liabilities ($26.3M).
Debt to Equity History and Analysis
Debt Level: CUTR's debt to equity ratio (13.8%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if CUTR's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CUTR has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if CUTR has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Cutera current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CUTR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CUTR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CUTR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CUTR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CUTR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dave Mowry (58 yo)
Mr. David H. Mowry, also known as Dave, is the Chief Executive Officer and Director at Cutera, Inc. since July 8, 2019. Mr. Mowry served as the Director, President and Chief Executive Officer of Vyaire Med...
CEO Compensation Analysis
Compensation vs Market: Dave's total compensation ($USD3.49M) is above average for companies of similar size in the US market ($USD1.80M).
Compensation vs Earnings: Insufficient data to compare Dave's compensation with company performance.
|CEO & Director||1.33yrs||US$3.49m||0.22% |
|Chief Financial Officer||0.25yr||no data||no data|
|Executive VP & Chief Technology Officer||3.25yrs||no data||no data|
|Vice President of Investor Relations & Corporate Development||no data||no data||no data|
|Director of Corporate Communications||no data||no data||no data|
|Vice President of Finance||no data||no data||no data|
Experienced Management: CUTR's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
|CEO & Director||1.33yrs||US$3.49m||0.22% |
|Independent Director||1.75yrs||US$196.93k||0.50% |
|Independent Director||1.75yrs||US$191.93k||0.074% |
|Independent Director||9.08yrs||US$208.49k||0.38% |
|Independent Director||16.58yrs||US$199.99k||0.25% |
|Independent Chairman||4.08yrs||US$201.74k||0.090% |
Experienced Board: CUTR's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 23.9%.
Cutera, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Cutera, Inc.
- Ticker: CUTR
- Exchange: NasdaqGS
- Founded: 1988
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$418.952m
- Shares outstanding: 17.63m
- Website: https://www.cutera.com
Number of Employees
- Cutera, Inc.
- 3240 Bayshore Boulevard
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CUTR||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Mar 2004|
|TJ9||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Mar 2004|
Cutera, Inc., a medical device company, engages in the research, development, manufacture, marketing, and servicing of laser and energy-based aesthetics systems for practitioners worldwide. The company off...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/12/02 00:09|
|End of Day Share Price||2020/12/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.